Schroder Investment Management Group Sells 315,800 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Schroder Investment Management Group reduced its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 20.0% during the third quarter, Holdings Channel reports. The institutional investor owned 1,264,695 shares of the company’s stock after selling 315,800 shares during the quarter. Schroder Investment Management Group’s holdings in Teva Pharmaceutical Industries were worth $27,242,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. CIBC World Markets Inc. lifted its holdings in Teva Pharmaceutical Industries by 9.6% in the third quarter. CIBC World Markets Inc. now owns 536,143 shares of the company’s stock worth $11,549,000 after buying an additional 46,887 shares during the period. FMR LLC lifted its holdings in Teva Pharmaceutical Industries by 19.1% in the third quarter. FMR LLC now owns 24,481,936 shares of the company’s stock worth $527,341,000 after buying an additional 3,921,785 shares during the period. Polaris Capital Management LLC lifted its holdings in Teva Pharmaceutical Industries by 9.0% in the third quarter. Polaris Capital Management LLC now owns 9,911,038 shares of the company’s stock worth $213,484,000 after buying an additional 817,964 shares during the period. Fosun International Ltd lifted its holdings in Teva Pharmaceutical Industries by 36.5% in the third quarter. Fosun International Ltd now owns 43,000 shares of the company’s stock worth $909,000 after buying an additional 11,500 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in Teva Pharmaceutical Industries by 11.4% in the third quarter. Janus Henderson Group PLC now owns 141,421 shares of the company’s stock worth $3,047,000 after buying an additional 14,500 shares during the period. 63.44% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have commented on TEVA. Mizuho restated a “buy” rating and issued a $28.00 price objective on shares of Teva Pharmaceutical Industries in a report on Thursday, August 16th. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, November 1st. Royal Bank of Canada set a $22.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Friday, November 2nd. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, November 7th. Finally, Wells Fargo & Co reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Friday, November 2nd. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average target price of $22.08.

TEVA stock opened at $21.54 on Friday. Teva Pharmaceutical Industries Ltd has a 52-week low of $14.05 and a 52-week high of $25.96. The company has a market cap of $22.27 billion, a PE ratio of 5.48, a price-to-earnings-growth ratio of 6.60 and a beta of 0.77. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 1.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.11. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.54 billion. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The firm’s quarterly revenue was down 19.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.00 earnings per share. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd will post 2.82 EPS for the current year.

In related news, VP Richard Daniell sold 2,488 shares of the firm’s stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total transaction of $58,940.72. Following the completion of the sale, the vice president now owns 2,488 shares of the company’s stock, valued at $58,940.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Deborah A. Griffin sold 2,376 shares of the firm’s stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total transaction of $56,334.96. Following the sale, the insider now directly owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The disclosure for this sale can be found here. Insiders have sold 6,531 shares of company stock valued at $152,749 in the last three months. 0.43% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2018/12/01/schroder-investment-management-group-sells-315800-shares-of-teva-pharmaceutical-industries-ltd-teva.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit